

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Edward Duncan BLAIR et al.

International Application No.: PCT/EP2003/007939

International Filing Date: July 17, 2003

For: *Transgenic Animal Models of HRV with Humani Icam-1 Sequences*

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed
- ☒ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
- ☒ A copy of the International Search Report which issued on International Application No. PCT/EP2003/007939 submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: 1/14/05


Julie D. McFalls
 Julie D. McFalls

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Attorney of Record: Virginia G. Campen
Registration No. 37,092

Date: 14 Jan 05
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483- 1012
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PG4871 USw	International APPLICATION NO. PCT/EP2003/007939
	APPLICANT Edward Duncan BLAIR et al.	
	International FILING DATE July 17, 2003	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page _____

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	A	WO02/19813	March 14, 2002	PCT		
	B	WO93/06850	April 15, 1993	PCT		
	C	EP0745 852 A	December 4, 1996	EP		

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

D	Staunton Dr., Guar et al., <i>Internalization of a major group human rhinovirus does not require cytoplasmic of transmembrane domains of ICAM-1</i> , Journal of Immunology 148: no. 10 3271-3274 (May 15, 1992)
E	Tallone T. Malin et al., <i>A mouse model for adenovirus gene delivery</i> , Proc Nat'l Acad Sci USA 98: No. 14 -pp. 7910-7905 (July 3, 2001)
F	Ockenhouse C. et al., <i>Plasmodium falciparum-infected erythrocytes bind ICAM-1 at a site distinct from LFA-1 MAC-1 and human Rhinovirus</i> , CELL 68 :63-69 (January 10, 1992)
G	Schafren DR et al., <i>Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21</i> , Journal of Virology, 71 , No. 1: 785-789 (January 1997)
H	Greve JM et al, <i>Mechanisms of Receptor-Mediated Rhinovirus Neutralization defined by two soluble forms of ICAM-1</i> , Journal of Virology 65, no. 11: 6015-6023 (November 1, 1991)
I	Vin et al., <i>Establishment of a Mouse Model for Human Rhinovirus Infection</i> , Journal of General Virology 67, no. 11: (November 1986)
J	Bella et al., <i>The structure of the two amino-terminal domains of human intercellular adhesion molecule-1 suggests how it functions as Rhinovirus Receptor</i> " VIRUS Research, 62 pp 107-117 (1999)
K	Lu Huifang et al., <i>"LFA-1 (CD11a/CD18) triggers hydrogen peroxide production by canine neutrophils"</i> , Journal of Leukocyte Biology, 68, No.; pp. 73-80 (July 1, 2000)
L	Tuthill Tobias J et al., <i>"Mouse Respiratory Epithelial cells support efficient replication of human Rhinovirus"</i> , Journal of General Virology, 84, No. 10 pp. 2829-2836 (2003)
M	Harris JR et al., <i>"Changes in Rhinovirus in Mouse Cells"</i> Journal of Virology", 77 no.8, pp. 4773-4780 (April 2003)